Approval summary for bortezomib for injection in the treatment of multiple myeloma

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 10; no. 12; pp. 3954 - 3964
Main Authors BROSS, Peter F, KANE, Robert, LEIGHTON, John, CHENG YI LIANG, LOSTRITTO, Richard T, MCGUINN, William D, MORSE, David E, RAHMAN, Atiqur, ROSARIO, Lilliam A, VERBOIS, S. Leigh, WILLIAMS, Grant, WANG, Yong-Cheng, FARRELL, Ann T, PAZDUR, Richard, ABRAHAM, Sophia, BENSON, Kimberly, BROWER, Margaret E, BRADLEY, Sean, GOBBURU, Jogarao V, GOHEER, Anwar, LEE, Shwu-Luan
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 15.06.2004
Subjects
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Boronic Acids - therapeutic use
Bortezomib
Clinical Trials as Topic
Drug Approval
Female
Humans
Male
Medical sciences
Middle Aged
Models, Chemical
Multiple Myeloma - drug therapy
Pharmacology. Drug treatments
Proteasome Endopeptidase Complex - metabolism
Pyrazines - therapeutic use
Time Factors
Tumors
United States
United States Food and Drug Administration
United States
Antineoplastic agent
Immunopathology
Bortezomib
Treatment
Immunoglobulinopathy
Lymphoproliferative syndrome
Malignant hemopathy
Injection
Myeloma
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.ccr-03-0781